HOME >> MEDICINE >> NEWS
ACTOS (pioglitazone HCl) to be studied in new trial

Washington, DC, June 9, 2006 Researchers today at the American Diabetes Association (ADA) 66th Annual Scientific Sessions presented data showing the relationship between baseline characteristics and cardiac risk factors in patients enrolled in a new clinical trial called CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne). This is the largest and longest study to examine the effects of ACTOS on measures of the atherosclerotic disease process in patients with type 2 diabetes, most of whom had no clinical evidence of heart disease.

"While earlier and smaller studies found that ACTOS reduced carotid intima-media thickness, given the size and duration of the CHICAGO trial, we hope to gather further information about the effect of ACTOS on blood vessel health and atherosclerosis," said Theodore Mazzone, M.D., F.A.C.P., professor of medicine and director of the Section of Endocrinology, Diabetes and Metabolism at the University of Illinois at Chicago. "We look forward to further study findings, as we hope they can provide important information and insight about management of cardiovascular disease in people with type 2 diabetes."

The CHICAGO trial is an 18-month, multicenter, randomized study that has enrolled 439 patients with type 2 diabetes, all from the Chicago area, thus the name of the study. The primary goal was to compare the effects of ACTOS versus glimepiride, a sulfonylurea, on carotid intima-media thickness (CIMT), defined as the thickness of the inner lining of a patient's neck arteries. It is also assessing the occurrence of cardiovascular events (i.e., death, heart attack and stroke) and cardiovascular disease risk factors among patients with type 2 diabetes.

CIMT is a preferred, noninvasive measure of atherosclerosis, which can lead to heart attack or stroke because of reduced or blocked blood flow through the arteries. CHICAGO will also examine another marker of atherosclerosis, coronary artery ca
'"/>

Contact: Amy Losak
917-865-6688
Ketchum
9-Jun-2006


Page: 1 2

Related medicine news :

1. ACTOS (pioglitazone HCl) demonstrates significant improvements in cardiovascular outcomes
2. ACTOS reduces stroke by almost 50 percent
3. New data shows ACTOS reduced heart attacks by 28 percent in people with type 2 diabetes
4. ACTOS (pioglitazone HCl) significantly improved components of diabetic dyslipidemia
5. ACTOplus met (pioglitazone HCl and metformin HCl)
6. Spinal manipulation in children studied
7. New blood thinner studied for patients with leg and lung clots
8. New use of 64-slice CT scan to be studied at HUP to help diagnose coronary artery disease in the ED
9. Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied
10. Long-term outcomes studied for stem cell transplant recipients
11. New treatments for common vaginal infection being studied

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... WASHINGTON (PRWEB) , ... August 04, 2020 , ... Today, ... Maternal and Child Health Programs (AMCHP) with the 2020 Innovation Station Best Practice Award. ... if, when and under what circumstances to get pregnant and have a child. One ...
(Date:8/3/2020)... ... August 03, 2020 , ... The process uses ... House, Google, Amelia Arena, the Phoenix airport, the Mayo Clinic, Ramstein Air Force ... to Global Plasma Solutions (GPS), the manufacturers of the system, most viruses and ...
(Date:7/31/2020)... (PRWEB) , ... July 31, 2020 , ... ... currently accepting new patients to The Dental Studio of Midland for groundbreaking ... provider. As a result, these patients are able to experience the many advantages ...
(Date:7/22/2020)... ... 2020 , ... Whatever we call them – sunspots, age spots, liver spots, ... notes Angie Seelal, a Certified Registered Physician Assistant specializing in Dermatology with Advanced ... and make us look older.” , In terms of the name, ‘sunspots’ or the ...
(Date:7/22/2020)... ... 22, 2020 , ... Ocean Tomo Transactions, LLC will auction ... processes from Brock University for jurisdictions throughout North America, Europe and Asia. ... provides the manufacturing processes of novel opioid related compositions for pain management as ...
Breaking Medicine News(10 mins):
(Date:8/5/2020)... ... August 04, 2020 , ... Millions of America’s seniors ... health and quality of life unless Congress and the Centers for Medicare & ... (ASHA) warns today. , At issue is CMS’s 2021 proposed Medicare Physician ...
(Date:8/3/2020)... ... August 03, 2020 , ... Seattle’s Infectious ... to amend and restate IDRI’s license with Immune Design, a wholly owned subsidiary ... the amendment, the parties have agreed to modify the licensed fields and indications ...
(Date:8/3/2020)... ... August 03, 2020 , ... LaVoieHealthScience (LHS), an integrated investor and ... Donna L. LaVoie, President, CEO and Founder of LHS, has been named to the ... 2005, the PharmaVOICE 100 has honored more than 1,500 industry executives for their contributions ...
Breaking Medicine Technology:
Cached News: